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Background: Patients with Alzheimer’s disease (AD) often present with apathy symptoms resembling the decreased
motivation observed in depressed patients. Therefore, differentiating the initial phase of AD from late life depression
may be difficult in some cases. Near-infrared spectroscopy (NIRS) is a functional neuroimaging modality that uses
near-infrared light to measure changes in hemoglobin concentration on the cortical surface during activation tasks.
The objective of this study was to investigate differences in brain activation associated with late life depression and
with AD by means of NIRS.
Methods: NIRS was performed in 30 patients with depression, 28 patients with AD, and 33 healthy controls, all aged
60 years or older. During two tasks, a verbal fluency task and a visuospatial task, changes in oxygenated hemoglobin
concentration in the frontal and parietal cortices were investigated.
Results: In the visuospatial task, cortical activation was lower in the depressed group than in the AD group, and
significant differences were observed in the parietal cortex.
Conclusions: NIRS can detect differences in brain activation between patients with late life depression and those
with AD. NIRS is a promising tool for the differential diagnosis of late life depression and AD.
Keywords: Near-infrared spectroscopy, Brain activation, Alzheimer’s disease, DepressionBackground
Apathy in dementia is often difficult to distinguish from
decreased motivation in depressed patients. Therefore,
careful observation of the clinical course may be re-
quired to differentiate late life depression from the initial
phase of Alzheimer’s disease (AD). Depression-related
and age-related factors mutually affect each other. For
this reason, late life depression tends to be accompanied
by cognitive dysfunction and clinical symptoms are
multifaceted, making diagnosis difficult. To discriminate
depression from dementia, brain imaging may be a help-
ful addition to a detailed examination of the patient’s
medical history and current findings. For this purpose,* Correspondence: hisashi@shinshu-u.ac.jp
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unless otherwise stated.near-infrared spectroscopy (NIRS) may offer a means to
aid the differential diagnosis of these conditions.
NIRS, a method for measuring brain function that was
developed during the 1990s, is used to measure changes
in regional cerebral blood flow (rCBF) associated with
brain activation. Using near-infrared light, NIRS can detect
rCBF changes as represented by increases in oxygenated
hemoglobin concentration ([oxy-Hb]) and decreases in de-
oxygenated hemoglobin concentration ([deoxy-Hb]), which
are considered to reflect cortical activity [1]. It has been
reported that the results of NIRS correlate strongly with
those of functional magnetic resonance imaging (fMRI)
[2]. The advantage of NIRS over other functional neuro-
imaging techniques such as fMRI is that subjects can be
examined more easily in the sitting position.
To date, several NIRS studies have compared findings
in patients with AD with those in healthy controls. In. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[oxy-Hb] in the prefrontal cortex during a verbal fluency
task (VFT), while Arai et al. [4] reported decreased brain
activation in both the frontal and parietal lobes during a
VFT. In addition, Zeller et al. [5] found activation deficits
in the parietal cortex during a visuospatial task. On the
other hand, in NIRS studies of late life depression, Matsuo
et al. [6] reported significantly less activation of the pre-
frontal cortex in AD, and several other studies have re-
ported hypofrontality [7-9]. However, we are not aware of
any studies that have used NIRS for a direct comparison of
late life depression and AD. We believe that such a com-
parison is of clinical significance, and could potentially aid
in the differential diagnosis of late life depression and AD.
Neuroimaging studies comparing the two conditions
include a report on single photon emission tomography
which revealed markedly decreased rCBF in the tem-
poral and parietal lobes in AD, while in the frontal lobe,
rCBF was markedly decreased in depression [10]. Previous
fMRI studies have shown inconsistent results regarding
the hemodynamic response in AD or depression, and none
have directly compared the activation patterns of both
conditions [11-18].
The objective of the present study was to investigate
differences in brain activation between late life depres-
sion and AD by means of NIRS. We examined activation
in the frontal and parietal cortices during two activation
tasks, a VFT and a visuospatial task, in patients with AD
or depression in comparison with healthy subjects as
controls. Given that several lines of evidence suggest the
involvement of executive deficits associated with frontal
lobe dysfunction in the pathophysiology of depression
[19,20] and that both frontal and parietal dysfunctions
are observed from the initial phase of AD [21-24], we
hypothesized that activation in the parietal cortex would
show a more marked decrease in patients with AD than
in those with depression.Table 1 Clinical data
Controls Depression Alzheimer’
(n = 33) (n = 30) (n =
Male:Female 11:22 9:21 10:1
Age (years) 69.6 ± 5.5 71.1 ± 6.8 76.6 ±
MMSE score 29.2 ± 1.2 26.6 ± 2.3 21.6 ±
FAB score 16.1 ± 1.2 14.1 ± 2.7 12.0 ±
CDR score 0 0.05 ± 0.2 0.8 ±
HAMD score 0.2 ± 0.8 10.7 ± 8.9 4.4 ±
VFT performance 41.3 ± 7.9 33.2 ± 12.2 33.9 ±
Benton Judgment of Line Orientation
performance
22.6 ± 6.6 12.5 ± 4.2 13.7 ±
Continuous values are shown as the means ± standard deviation. Abbreviations: AD
freedom, FAB Frontal Assessment Battery, HAMD Hamilton Rating Scale for Depress
Chi-squared value.Methods
Participants
Participants were male and female patients aged 60 years
or older receiving inpatient or outpatient care at the
Department of Psychiatry, Shinshu University Hospital,
Japan. In total, 33 patients met the Diagnostic and Stat-
istical Manual of Mental Disorders-IV diagnostic cri-
teria for depression and 32 other patients met that for
AD. Patients who met the diagnostic criteria for both
depression and AD were excluded from the study. All
patients had been diagnosed by psychiatrists. In
addition, 33 healthy subjects aged 60 years or over who
were members of municipal physical fitness clubs, who
had no history of psychiatric or neurological disease,
and were no taking psychotropics were enrolled as con-
trols (Table 1). All participants were right-handed. All
patients were taking psychotropic medication. Patients
with depression were treated with antidepressants (5
with amitriptyline, 1 with maprotiline, 6 with sertraline,
2 with fluvoxamine, 3 with escitalopram, 10 with dulox-
etine, 2 with milnacipran, 3 with mirtazapine, and 1
with mianserin), and patients with AD were treated
with anti-dementia drugs (27 with donepezil, 4 with
memantine, and 1 with galantamine). Head MRI was
conducted for all patients, and those with findings that
would affect rCBF, such as gross cerebral infarction or
cerebral aneurysm, were excluded. Also excluded were
patients with endocrine, metabolic, or neurological
disorders.Ethics
This study was approved by the Ethics Committee of
Shinshu University School of Medicine (No. 1488), and
all participants provided written informed consent. For
patients with AD, written consent was also obtained
from their guardians.s Disease
Statistics
Post hoc comparisons
28) D vs AD D vs HC AD vs HC
8 χ2 = 0.22, df = 2, p = 0.90
6.9 F = 9.66 p < 0.001 p = 0.005 p = 0.603 p < 0.001
4.4 F = 52.7 p < 0.001 p < 0.001 p = 0.002 p < 0.001
3.2 F = 20.1 p < 0.001 p = 0.008 p = 0.005 p < 0.001
0.4 p < 0.001 p < 0.001 p = 0.065 p < 0.001
7.1 F = 20.3 p < 0.001 p = 0.001 p < 0.001 p = 0.037
10.1 F = 6.19 p = 0.003 p = 0.963 p = 0.006 p = 0.015
8.5 F = 21.6 p < 0.001 p = 0.779 p < 0.001 p < 0.001
Alzheimer’s disease, CDR Clinical Dementia Rating, D depression, df degrees of
ion, HC healthy controls, MMSE Mini Mental State Examination, χ2
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All participants were assessed using the 21-item Hamilton
Rating Scale for Depression (HAMD) [25], Clinical De-
mentia Rating (CDR) [26], Mini Mental State Examination
(MMSE) [27], and Frontal Assessment Battery (FAB). The
FAB assesses decreases in frontal lobe function and com-
prises 6 test items [28]. All tests were conducted by a single
trained clinical psychotherapist.
NIRS measurements
Changes in [oxy-Hb] and [deoxy-Hb] were measured using
an NIRS system (FOIRE-3000; Shimadzu Corporation,
Kyoto, Japan). Absorption was measured at three wave-
lengths of near-infrared light (780, 805, and 830 nm), and
[oxy-Hb] and [deoxy-Hb] levels were calculated accord-
ing to the Lambert-Beer law based on the differences in
absorption between the three wavelengths. The NIRS sys-
tem can measure changes in hemoglobin concentrations
at a range of approximately 2-3 cm from the surface of
the skull. The distance between each pair of emission
and detector probes was 3.0 cm, and the measurement
area between each pair was defined as a ‘channel (CH)’.
In total, 22 channels were positioned in a 6 × 12 cm area
covering the frontal and parietal cortices, with CH 1-22
corresponding to the frontal cortex and CH 23-44 to the
parietal cortex. The lowest probes in the frontal cortex
were positioned along the Fp1-Fp2 line according to the
International 10-20 system. Probes for the parietal cortex
were positioned such that Pz was located at the center.
Activation tasks
The NIRS study was performed with the participants sit-
ting relaxed in a chair and facing the screen of a desktop
computer. NIRS measurement was performed using a
block design. A 30-s rest period was established,
followed by a 60-s task period and another 30-s rest
period. This sequence was repeated 3 times in succes-
sion. Based on previous studies [5,29], we applied the
VFT and a visuospatial task (Benton Judgment of Line
Orientation). The latter is a standardized test assessing
the ability to recognize the angle of two lines, and it has
been reported that task performance is decreased in AD
[30]. A 2-3-min interval was established between the
VFT and visuospatial task. During the rest period of the
VFT, participants repeated the Japanese syllables “a, i, u,
e, o” (corresponding to “A, B, C…” in English) as a con-
trol. During the task period, participants were asked to
respond with as many words as possible beginning with
the Japanese morae (syllables) “ki”, “o”, “i”, “sa”, “ta”, “a”,
“ku”, “u”, and “ko”. The task was performed starting with
words beginning with “ki”, and oral instructions were
given every 20 s to change to words beginning with the
next mora. Participants were asked to perform an active
control task during the rest period so that the NIRSsignal caused by vocalization could be subtracted from
the NIRS signal during the task period. Task perform-
ance was scored as the number of words spoken during
the VFT. In the visuospatial task, participants were asked
to repeat 11 random numbers displayed on the screen
during the rest period. Then, during the task period, the
Benton Judgment of Line Orientation was displayed on
the computer, with the next task displayed after the sub-
ject responded. Task performance was scored as the
number of correct responses. While these tasks were be-
ing performed, changes in hemoglobin concentrations
were measured using the 44-channel NIRS.
Data analysis
Clinical data were compared between controls, depressed
patients, and patients with AD by analysis of variance
(ANOVA) or the Krusksal-Wallis test for continuous
variables and the Chi-squared test for categorical vari-
ables. Post hoc comparisons were performed using
Tukey’s honestly significant difference test for ANOVA
and the Mann-Whitney U-test for the Kruskal-Wallis test.
NIRS data with significant artifacts were excluded
from the analysis. Thus, data from 30 patients with de-
pression, 28 patients with AD, and 33 healthy controls
were analyzed. Although [oxy-Hb], [deoxy-Hb], and total
hemoglobin concentrations can be measured by NIRS,
we concentrated on [oxy-Hb], which correlates best with
changes in rCBF [31]. After averaging the results of
three consecutive runs of the same task for each partici-
pant, a baseline correction was performed setting the
amount of change in [oxy-Hb] at the start of the task as
zero. We defined cortical activation as the difference be-
tween average [oxy-Hb] during the pre-task period and
that during the task period. NIRS measurements were
the product of the change in hemoglobin concentration
and the optical path length; however, the optical path
length differed according to measurement site. Conse-
quently, because all channels were independent, the
cortical activation in each of the 44 channels was com-
paratively analyzed. Since none of the cortical activation
data followed a normal distribution as determined by
the Shapiro-Wilk test, the data were compared between
the three groups using the Kruskal-Wallis test. Post hoc
comparisons between the groups were performed using
the Mann-Whitney U-test. Because data were analyzed
for 44 channels, the false discovery rate (FDR) was used
to correct for multiple comparisons [32]. A corrected
p-value of less than 0.05 was considered significant.
Spearman’s rank correlation coefficient was used to
analyze correlations between clinical data and the cor-
tical activation observed in each channel, and FDR was
used to correct for multiple comparisons. Stepwise logis-
tic regression analysis was performed for patients with
depression and those with AD to determine the optimal
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analysis was conducted as a forward stepping procedure
based on a likelihood ratio test, with p < 0.05 for variable
inclusion and p > 0.1 for variable exclusion from the
model. The cortical activations of the 44 channels were
used as potential predictor variables. Nagelkerke’s coeffi-
cient of determination was used to approximate the per-
cent of variance explained by the model [33]. The area
under the receiver operating characteristic curve (AUC)
was also used to determine the predictive power of the
logistic model. The predicted probability with the high-
est Youden index was selected as the optimal cut-off




MMSE and FAB scores were decreased in the order of
healthy controls, patients with depression, and patients
with AD, confirming a decrease in cognitive function
(Table 1). MMSE and CDR scores confirmed that the
patients with AD were in the initial phase of the disease.
HAMD scores indicated the severity of depression was
mild [34]. Task performance in both patient groups was






Figure 1 General cortical activation in the three participant groups. S
verbal fluency task (a) and visuospatial task (b). Upper figures show the activa
parietal cortex. The color bar indicates [oxy-Hb] (mM·cm). Note that the scale
healthy controls; D, depression; AD, Alzheimer’s disease; [oxy-Hb], oxygenated0.779 in the Benton Judgment of Line Orientation). The
results of head MRI showed temporal and parietal lobe
atrophy in all patients with AD. No patients with depres-
sion presented notable pathological findings.
NIRS data
General cortical activation patterns
Figure 1 shows the topography of cortical activation of
each group.
Cortical activation in the VFT
The Kruskal-Wallis test revealed significant differences
in CH 1 (p = 0.030), CH 2 (p = 0.050), CH 3 (p = 0.016),
CH 12 (p = 0.029), CH 13 (p = 0.021), CH 30 (p = 0.014),
CH 34 (p = 0.005), CH 35 (p = 0.001), CH 36 (p = 0.045),
CH 39 (p = 0.022), and CH 43 (p = 0.031). The Mann-
Whitney U-test showed significant differences only be-
tween the healthy controls and patients with depression.
Cortical activation in the depressed group was de-
creased in comparison with healthy controls (Figure 1a).
Significant differences were observed in CH3 of the
frontal lobe (p = 0.043) and in CH 30 (p = 0.043), CH 34
(p = 0.041), CH 35 (p = 0.008), CH 39 (p = 0.043), and
CH 43 (p = 0.043) of the right parietal lobe (p-values are
FDR corrected) (Figure 2).AD
AD
uperimposed images on 3-D MRI represent cortical activation in the
tion of the frontal cortex, and lower figures show the activation of the
of the color bar differs between figures (a) and (b). Abbreviations: HC,
hemoglobin concentration.
Figure 2 Comparison of VFT results between the depressed group and healthy control. Upper panels: The locations of the 44 channels on
the head are indicated by yellow dots. The frontal cortex is on the left; the parietal cortex on the right. Significant differences are observed in 6 of
the 44 channels indicated by red circles. Lower panels: Grand average waveforms of changes in [oxy-Hb] of CH 3 (left) and CH 34 (right) in the
three groups, both of which show significant differences. Blue line, healthy controls; red line, AD group; black line, depressed group. In all three
groups, during the rest period from −30 to 0 s, there are slight changes in [oxy-Hb], and during the task period from 0 to 60 s, [oxy-Hb] associated
with brain activation is increased. At 60 s (when the task concluded), [oxy-Hb] is decreased. Abbreviations: D, depression; AD, Alzheimer’s disease.
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The Kruskal-Wallis test revealed significant differences in
CH 15 (p = 0.033), CH 17 (p = 0.046), CH 18 (p = 0.036),
CH 24 (p = 0.006), CH 25 (p = 0.006), CH 26 (p = 0.017),
CH 28 (p = 0.031), CH 31 (p = 0.002), CH 32 (p = 0.011),
CH 34 (p = 0.039), CH 38 (p = 0.002), and CH 41
(p = 0.042). The Mann-Whitney U-test showed significant
differences only between the depressed group and the AD
group, where cortical activation was relatively decreased in
the depressed group (Figure 1b). Significant differences
were observed in CH 24 (p = 0.037), CH 25 (p = 0.020),
CH 31 (p = 0.020), CH 32 (p = 0.035), and CH 38
(p =0.014) of the parietal lobe (p-values are FDR
corrected) (Figure 3).Correlations between cortical activation and clinical data
Cortical activation did not correlate significantly with
age, task performance, or score on the MMSE, FAB,
CDR, or HAMD in any of the participant groups.Results of logistic regression analysis
The only channel with significance for predicting diag-
nosis during the visuospatial task was CH 38. Nagelk-
erke’s coefficient of determination showed a variance of
29.6% in the model. The total AUC was 0.769. Theoptimal cut-off point of cortical activation measured by
CH 38, as determined using the Youden index, was
0.0015. The sensitivity and specificity for differentiating
patients with depression from those with AD were
71.5% and 70.0%, respectively. Cortical activation during
the VFT did not significantly predict diagnosis.Discussion
The objective of this study was to investigate the differ-
ences in brain activation between late life depression
and AD. The results revealed that cortical activation in a
visuospatial task was significantly lower in the parietal
cortex of the depressed group than in that of the AD
group. Similar but non-significant tendencies were seen
in the VFT. Contrary to our hypothesis, parietal activa-
tion was lower in the depressed group than in the AD
group. This was due to the fact that the activation was
decreased in the depressed group in both the frontal and
parietal cortices, while in the AD group, cortical activa-
tion was maintained. Figure 1 shows the general cortical
activation patterns of the NIRS measurement area. Dif-
ferences in cortical activation between the three groups
were observed across the whole measurement area, sug-
gesting an overall decrease in [oxy-Hb] change across
the whole brain in patients with depression but not in
Figure 3 Comparison of visuospatial task results between the depressed group and AD group. Significant differences are seen in 5 of the
44 channels indicated by red circles. The graphs show the grand average waveforms of changes in [oxy-Hb] of CH 32 and CH 38 in the three
groups, 2 of the 5 channels which showed significant differences.
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parietal lobe and precuneus was significantly higher in
patients with AD than in those with depression. Superior
parietal lobe is associated with spatial orientation and
plays a role in maintaining the internal representation of
the body's state [35]. Precuneus is involved in a variety
of functions including visuo-spatial imagery, episodic
memory retrieval, and self-processing operations [36].
The present results may reflect the difference in these
functions between patients with AD and those with
depression.
Previous NIRS studies have reported decreased frontal
activation in patients with depression compared with
healthy controls [6,9]. However, to our knowledge, no
studies have examined the activation of the parietal cor-
tex in patients with depression. The present study
showed decreased activation in the parietal cortex, as
well as in the frontal cortex. In the VFT, significant de-
creases were observed in the right parietal cortex in
comparison with healthy controls.
On the other hand, cortical activation was maintained
in the AD group. Parietal dysfunction in AD is observed
from the initial phase of the disease [21-23]. As a result,
parietal activation was expected to be more decreased in
the AD group than in the depressed group, but we actu-
ally found that parietal activation was significantly de-
creased in the depressed group, despite the virtually
equivalent task performance scores. Although NIRS
measures changes in rCBF associated with neuralactivity, based on the theory of neurovascular coupling
[37], we believe that changes in rCBF do not necessarily
correspond to task performance and cognitive function
in patients. Two fMRI studies demonstrated that the
parietal region was more activated in normal individuals
at high risk for AD than in low-risk individuals, although
the level of task performance was identical in both
groups [17,18]. Accordingly, these studies speculated
that greater cognitive effort was required by the high-
risk group to achieve the same level of performance as
the low-risk group. A positron emission tomography ac-
tivation study showed that brain activity may increase to
compensate for the declined cognitive function in pa-
tients with AD [38]. In the present study, the AD group
with decreased cognitive function may have required
more cognitive effort to achieve the same task perform-
ance as the depressed group, possibly resulting in rela-
tively greater parietal activation in the AD group.
According to the compensation hypothesis [39], older
adults with impaired cognitive function perform equiva-
lently to younger adults but display overactivation in
the brain cortex at a lower level of task demand; at a
higher level of task demand, the brain cortex becomes
underactivated and the performance becomes impaired
in older adults compared with younger adults. A similar
mechanism may explain the difference in the cortical
activation between the AD and depressed groups. The
significant differences in cortical activation during the
visuospatial task between these groups may be explained
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AD group caused by the visuospatial task, which is a low-
level task. The differences in cortical activation, however,
cannot be completely explained by the compensation hy-
pothesis, because neurovascular coupling may be dis-
rupted in patients with AD [40,41].
Previous NIRS studies have reported that parietal acti-
vation was decreased in patients with AD compared
with healthy controls [4,5]. In the present study, how-
ever, no significant differences were observed between
the two groups. Such inconsistency may be due to the
differences in the type and duration of the tasks per-
formed, as well as disease severity. Furthermore, the sig-
nificant difference in age between the patients with AD
and healthy controls may have influenced the results, be-
cause neurovascular coupling is also known to be altered
by normal aging [41]. Vermeij et al. [42] reported that
the effects of aging on the time course of the
hemodynamic response in the prefrontal cortex must be
taken into account when interpreting the results of neu-
roimaging studies.
A few points could be improved in the present study.
The first is that NIRS could have been used to measure
blood flow in the scalp in addition to rCBF [43-45]. The
extent to which scalp blood flow is included in our data
is unknown; therefore, future studies should examine
systemic parameters such as heart rate, blood pressure,
end-tidal CO2, skin conductance, and scalp blood flow
in order to separate the effects of systemic blood flow
from NIRS signals due to neural activity [44,46]. Second,
the effects of drugs cannot be ruled out. Previous studies
have shown that acetylcholine-esterase inhibitors influ-
ence neurovascular coupling [47]. Other studies have re-
ported that administration of antidepressants have
influence on [oxy-Hb] changes [48-50]. However, a re-
view of neuroimaging studies on bipolar disorder by
Phillip et al. [51] reported neither significant nor ameli-
orative effects of psychotropic medications on abnormal
structural and functional neuroimaging measures. Fur-
thermore, several studies showed no significant correla-
tions between cortical activation measured by NIRS and
the dose of psychotropic medications [52-54]. Third, the
participants in this study were not matched by age. We
know that in the frontal cortex, the cortical activation
patterns change with age [42,55]. However, in our data,
no significant correlations were found between age and
cortical activation, and the effects due to age differences
are considered to be minor. Fourth, the effect of cere-
brocortical atrophy in AD cannot be ruled out. When
the layer of cerebrospinal fluid thickens due to cerebral
atrophy, the sensitivity of NIRS measurements decreases
[56]. Fifth, the depressed group comprised patients with
partially or fully remitted symptoms of depression with
low HAMD scores. It remains to be elucidated whetherthe present findings apply during severe depressive epi-
sodes. Lastly, depression rating scales validated for use
with elderly patients, such as the Geriatric Depression
Scale [57], are possible alternatives to the HAMD. Fur-
ther studies are required to investigate these issues.
Conclusions
NIRS revealed differences in brain activation between
late life depression and AD. NIRS is a promising tool to
assist in the differential diagnosis of these conditions.
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